Probably Genetic

Probably Genetic

Provides free at-home genetic testing services

About Probably Genetic

Simplify's Rating
Why Probably Genetic is rated
B+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Early VC

Total Funding

$10.9M

Headquarters

San Francisco, California

Founded

2019

Overview

Probably Genetic provides genetic testing services specifically for individuals with rare diseases. Their main offering is a free at-home genetic testing kit, which allows patients to collect DNA samples conveniently from their homes. After the samples are sent back, the company analyzes the DNA to help patients receive accurate diagnoses and genetic counseling. Unlike many competitors, Probably Genetic operates its program at no cost to eligible patients, funding the service themselves and maintaining control over the data collected. This data, once de-identified, can be shared with research institutions and pharmaceutical companies, creating a revenue stream for the company while supporting rare disease research. The goal of Probably Genetic is to improve the diagnostic process for rare disease patients, providing them with essential insights and support in a streamlined and patient-friendly manner.

YC Company
📈
Significant Headcount Growth
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased collaboration with patient advocacy groups enhances reach and credibility.
  • Growing trend of at-home healthcare supports their business model.
  • Rising demand for personalized medicine boosts genetic testing services.

What critics are saying

  • Reliance on partnerships could pose risks if they dissolve or underperform.
  • Business model may face scrutiny from privacy advocates, affecting trust.
  • Competitive landscape in genetic testing could impact market share.

What makes Probably Genetic unique

  • Offers free at-home genetic testing for rare disease diagnosis.
  • Focuses on patients misdiagnosed with autism spectrum disorder.
  • Aggregates de-identified data for research and pharmaceutical partnerships.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$10.9M

Above

Industry Average

Funded Over

2 Rounds

Notable Investors:
Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Benefits

Unlimited Paid Time Off

Hybrid Work Options

Remote Work Options

Company Equity

Health Insurance

Dental Insurance

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

↑ 3%

1 year growth

↑ 11%

2 year growth

↑ 7%
Trending Topics
Dec 29th, 2023
Calm/Storm: 4,5 Mio. Euro 2023 Investiert – Und 2024 Kann Noch Einmal Blutig Werden

Aus Österreich heraus den aktivsten HealthTech-Fonds Europas zu starten, ist eine Leistung, die sich Lucanus Polagnoli und sein Team auf die Segel, pardon, Fahnen, schreiben können: Doch seit 2023 investiert Calm/Storm Ventures nicht nur in Digital-Health-Startups, sondern hat auch einen eigenen Fonds fĂŒr Startups aufgelegt, mit dem auch in Startups aus anderen Branchen investiert, solange diese von Österreicher:innen (mit-)gegrĂŒndet wurden. „Mit insgesamt 17 Neu-Investments ist das Portfolio auf 75 Startup-Unternehmen gewachsen. Zusammen mit 21 Follow-On Transaktionen innerhalb des Portfolios wurden 2023 insgesamt ĂŒber 4,5 Millionen Euro investiert“, so Calm/Storm-CEO Lucanus Polagnoli zu Trending Topics. Man wĂŒrde besonders oft in so genannte Stealth-Startups investieren, also Jungfirmen, die noch gar nicht auf dem Markt sind. Ein Beispiel ist Mirror, das neue Startup der ehemaligen GrĂŒnder von Gorillas, Kagan SĂŒmer und Ugur Samut. Wert wird auf DiversitĂ€t gelegt; Die HĂ€lfte der Teams, in die Calm/Storm investieret, sind divers, und 30% aller CEOs seien Frauen

U.S. Securities and Exchange Commission
Nov 3rd, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

PRWeb
Aug 3rd, 2023
The Scn2A Foundation And Probably Genetic Partner To Make Genetic Test

scn2a foundation probably genetic partner to accelerate scn2a diagnosis. . “By increasing the ability to test for rare disorders, there will be a better opportunity to diagnose and treat patients with rare diseases. Lukas and his team are doing amazing work and we’re happy to help in any way we can” said Jason Curry, Founder of The SCN2A Foundation

APBDRF
Jul 18th, 2023
Foundation partners with Probably Genetic to address diagnostic challenges

Apbdrf is thrilled to announce that the APBD Research Foundation has partnered with Probably Genetic to increase access to genetic testing within its community.

There are no jobs for Probably Genetic right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →